Medincell

« Medincell, up 133% since January 1, is on its way to finishing at the top of the rankings of a Parisian stock market » (Les Echos, Les Echos Bourse / Investir, Euronext) Thank you to all our shareholders who have supported us. Let's keep growing together to change patients live all around the world through impactful innovations. Happy Holidays to all! https://lnkd.in/eQQTgA3n

We are proud to announce that Medincell will be included in the Euronext SBF 120 index, one of the most significant benchmarks of the French economy, and the CAC Mid 60 index. This milestone reflects our continued growth and performance just six years after our IPO. This inclusion, effective December 20 It’s more than a recognition, it’s an opportunity for increased visibility and trading activity as we continue to grow and deliver innovative solutions. Thank you to everyone who has supported us in reaching this significant milestone. Let’s continue building the future together! Learn more about the SBF 120 and CAC Mid 60: - SBF 120 Index: https://lnkd.in/eyPKn9bp - CAC Mid 60 Index: https://lnkd.in/eTSRneHm Press release: https://lnkd.in/e8EAPqse #MedinCell #SBF120 #CACMid60 #Innovation #Growth #Milestone

Medincell and AIC Announce New Positive Phase 3 Results for mdc-CWM We're thrilled to share promising results from a major subgroup analysis of Phase 3 study for mdc-CWM, targeting post-surgical pain management and recovery in patients undergoing Total Knee Replacement (TKR).   Key Highlights from the Subgroup (First TKR Patients, 108 out of 151 participants): ✅ 70% reduction in opioid users at 3 months post-surgery. ✅ 28% reduction in total opioid consumption during the first 3 months post-surgery. ✅ Lower daily knee pain observed over multiple time points (3 & 7 days, 2 & 6 weeks, 3 months). ✅ Faster recovery: Patients achieved the critical 100-degree range of motion milestone significantly earlier. ✅ Improved outcomes: Significant enhancements in pain, inflammation, and functional recovery.   This subgroup, consisting of patients undergoing their first TKR, demonstrated greater treatment benefits compared to the overall trial population, which included second TKR patients.   Based on these compelling findings, our future clinical development efforts will focus on this subgroup, with plans to commence in 2025, pending FDA agreement. Press release: https://lnkd.in/e4hRzkFZ   #Medincell #Innovation #PainManagement #OpioidReduction #Phase3Results #ClinicalResearch #TotalKneeReplacement

Join us on Tuesday, December 10, 2024, for the presentation of our Half-Year Results: 🇫🇷 French session at 6:00 PM CET: https://lnkd.in/dJGuGaVD 🇬🇧 English session at 7:00 PM CET: www.medincell.com/live-en Stay informed about our progress and strategic updates. #MedinCell #CorporateEvent #HYResults #Innovation

Looking forward to taking part in Jefferies London Healthcare Conference (November 19-21, London, UK) Christophe Douat and Richard Malamut to make a presentation on Nov. 20 at 8:30 am GMT Live broadcast and replay: https://lnkd.in/ewK9Ymhe #JefferiesHealthcare

Today, our partner Teva Pharmaceuticals shared promising updates as part of its Q3 2024 results: > UZEDY® : Revenue Outlook Raised: 2024 target now $100 million, up from $80 million! Strong U.S. Commercial Uptake: $75 million revenue year-to-date with $35 million in Q3 alone. > Olanzapine Long-Acting Injectable (TV-'749 / mdc-TJK): 100% of targeted injections completed for submission without PDSS—a significant step in advancing the treatment journey for patients in need. Press release: https://lnkd.in/ekbEe8Cs #HealthcareInnovation #Schizophrenia

📢 We will participate to key investor conferences this November and December! Meet our management team to discuss our innovations and growth plans: Truist Securities BioPharma Symposium: November 7, New York, NY UBS Global Healthcare Conference: November 11-14, Ranch Palos Verdes, CA (Presentation: November 12, 8:00 am PST) Jefferies London Healthcare Conference: November 19-21, London, UK (Presentation: November 20, 8:30 am GMT) Evercore ISI HealthCONx Conference: December 3-5, Coral Gables, FL (Fireside chat: December 4, 1:45 pm ET) Interested in connecting? Contact Grace Kim (grace.kim@medincell.com) or through the conference organizers. #Medincell #InvestorRelations #HealthcareInnovation

🔁 23rd European Society for Vector Ecology (ESOVE) Conference was held in Montpellier from 14-17 October 2024. This year's theme, One Health in Action, highlighted exciting new developments in bridging vertebrate and plant health communities. Angelique Porciani from IRD, Montpellier, presented promising results on the benefits of using Long-Acting Injectable (LAI) ivermectin in livestock, leveraging Medincell's BEPO® technology, to combat malaria transmission in areas where humans and livestock are in close proximity. 🌍 This breakthrough, developed through a strong consortium with IRD, CIRDES, IRSS Burkina Faso, Justus Liebig University Giessen, and Medincell, is another step toward sustainable and impactful vector control solutions. #OneHealth #ESOVE2024 #VectorControl #GlobalHealth #MalariaControl #LAI #Medincell #Sustainability

Looking forward to taking part in PODD 2024, a key event in the world of drug delivery. 📅  On October 28th at 3:30 PM,Christophe Roberge will share insights on how Medincell is innovating within the long-acting injectables space. Sebastien Enault will also be attending, and we look forward to engaging with fellow attendees as we explore the future of drug delivery. #PODD2024 #DrugDelivery #Innovation #LongActingInjectables

Participez à notre Webinaire Recherche & Développement le jeudi 10 octobre à 18h00 Rejoignez-nous pour une session en direct avec Sebastien Enault, Richard Malamut et Adolfo Lopez Noriega, qui répondront à vos questions. Pour vous connecter : https://lnkd.in/eGdKnbAr Vous pouvez envoyer vos questions d'ordre scientifique et médical à communication@medincell.com, ou interagir en direct via le module de messagerie pendant la réunion. [Réunion en français]